Dr. Robert Anderson
"My passion is in discovery and advancing scientific innovation to meet clinical need."
I have academic, clinical and commercial expertise in medicine, immunology and biopharma. My interests are in clinical medicine and translational immunology focused on antigen-specific T cells, cytokines, immune tolerance, specific immunotherapy and T-cell diagnostics. I currently divide my time between clinical practice in gut immune and inflammatory diseases as a gastroenterologist, and leading innovation and development of a new ultrasensitive antigen-specific T-cell diagnostic. I am expert in clinical and immunological aspects of coeliac disease serving as current President of the International Society for the Study of Coeliac Disease and as consultant to many biopharma companies developing novel therapies for coeliac disease. I have co-founded three private biotech companies in Australia & USA with venture funding of over US$80m (Nexpep, ImmusanT and Novoviah). I am inventor and developer of a first-in-class peptide immunotherapy (Nexvax2) for coeliac disease that advanced to Phase 2b and also of the Novoleukin whole blood T cell test now marketed to biopharma and academia. I have co-authored 85 peer-reviewed publications with 5,142 citations; my h-index is 36 and Google h-index 39; I an named inventor on 60 granted and 92 patents applications (19 patent families). I was awarded the 2023 Celiac Disease Foundation Prize in Excellence in Celiac Disease Research. My home is in Australia, but I was born and educated in New Zealand and lived for extended periods in the UK and USA and have worked in senior academic, clinical and commercial executive roles.
